Director: Robert Z. Orlowski, M.D., Ph.D. (MD Anderson)
Co-Director: Qing Yi, M.D., Ph.D. (MD Anderson)
The Developmental Research Program (DRP) will provide seed funding to meritorious translational projects that have the potential for significantly advancing our ability to prevent, detect, diagnose, stage, or treat multiple myeloma. Project proposals will be selected in a rigorous, peer-reviewed, two-tiered process, starting with a once-yearly request for applications that will be communicated to investigators at all three participating institutions. In this first round, proposals will be limited to four pages, and required to assume the format of an NIH R01 application, incorporating specific aims, background and significance, preliminary studies, and research design and methods. The authors of those selected by the DRP Director and Co-Director will be invited to submit a full, ten-page application, using the same format with the inclusion of a budget and justification. During this second tier, proposals will be reviewed by the DRP Review Committee, which will include Leaders and/or Co-Leaders of each of the SPORE Projects, Directors and/or Co-Directors of SPORE Cores, and at least four members of the External Scientific Advisory Board, and four members of the Internal Scientific Advisory Board. Up to four projects each year will be selected for funding and supported for one year, during which progress reports will be monitored every six months. Renewal of support may be possible for a second year, but will require the project to successfully compete with the next year’s pool of proposals. Through this mechanism, the DRP’s Specific Aims are:
- Specific Aim 1. Support of novel, highly translational research projects that take maximum advantage of the new research opportunities afforded by the SPORE.
- Specific Aim 2. Build and foster new collaborations among scientists within SPOREs, or with scientists outside the SPORE mechanism.